For the first time in more than a century of insulin therapy, children with type 1 diabetes have a mealtime insulin option that requires no needle.
The FDA approved Afrezza (insulin human inhalation powder; MannKind Corporation) for use in children and adolescents ages 6 and older with type 1 or type 2 diabetes on May 29, 2026 — expanding the drug's indication from adults to the pediatric population for the first time since Afrezza was originally approved in 2014.
The approval was based on data from the INHALE-1 clinical trial, a 26-week, open-label, randomized study comparing Afrezza plus a basal insulin injection against standard multiple daily injections in pediatric patients with type 1 diabetes. The trial found that Afrezza produced comparable blood sugar control alongside measurably less weight gain and significantly higher treatment satisfaction among children and their parents.
Why This Matters
Injection anxiety in children with type 1 diabetes is not a minor compliance issue. It is a documented, clinically significant barrier that drives skipped doses, inconsistent blood sugar control, and long-term complications — particularly in school settings where children must administer insulin independently and privately.
Type 1 diabetes requires mealtime insulin before or with every meal. For a child receiving multiple injections per day, that means several needle sticks that cannot be skipped or delayed without consequences. The emotional and behavioral burden compounds over years.
Afrezza delivers ultra-rapid-acting insulin through a small, portable inhaler used at the beginning of meals — no needles, no mixing, no refrigerated pens to carry. The device is roughly the size of a whistle and produces no visible plume. For children in classroom or cafeteria settings, it offers a degree of discretion that injection therapy cannot provide.
What We Know So Far
The INHALE-1 trial was a 26-week, randomized clinical study comparing Afrezza plus a basal insulin injection against multiple daily injections (MDI) in pediatric patients ages 4 to 17 with type 1 diabetes. The FDA's approval decision was based on this data and more than two decades of postmarketing safety experience with Afrezza in adults.
Key findings from the trial, as presented at the American Diabetes Association's 2026 Scientific Sessions in New Orleans:
- Blood sugar control : In children with well-controlled diabetes (HbA1c ≤ 9.5%), Afrezza achieved noninferior mean HbA1c and comparable time-in-range versus standard injected insulin analogs at 26 weeks
- Treatment satisfaction : Pediatric patients achieving HbA1c below 8% at 26 weeks reported statistically greater treatment satisfaction with Afrezza — a finding that held across both teenagers and their parents
- Weight gain : Afrezza users had measurably less weight gain compared to the injected insulin group — a clinically relevant secondary benefit, as weight gain is a known side effect of insulin therapy
- Lung function : No meaningful difference in FEV1 (a measure of lung capacity) was observed between Afrezza and MDI-treated patients after 26 weeks
"Inhaled insulin is the fastest acting insulin available and is a valuable alternative to injected analog insulin. Afrezza should be available as an option to all children and adults with type 1 diabetes," said Dr. Michael J. Haller, professor and chief of pediatric endocrinology at the University of Florida, and lead author of the INHALE-1 study.
Where the Clinical Benefit Is Greatest
Afrezza is not intended to replace basal (long-acting) insulin — children still require one daily injection of a basal insulin. What Afrezza eliminates is the requirement for multiple daily mealtime injections, which represent the majority of the needle burden for children on standard intensive therapy.
The patients most likely to benefit from Afrezza specifically are:
- Children with documented injection anxiety that drives missed doses
- Adolescents in school settings who have difficulty administering injections privately
- Families seeking to reduce the daily emotional burden of diabetes management
- Children who have been using automated insulin delivery (AID) systems and want a bolus option that does not require subcutaneous infusion
The product's mealtime dosing flexibility — administered with the first bite of food — may be a contributing factor, particularly for pediatric patients with variable daily schedules, according to Dr. Kevin Kaiserman, who presented data on Afrezza at the ADA 2026 Scientific Sessions.
What the Evidence Shows — and What It Does Not
Afrezza's primary limitation is its dosing structure. Unlike injectable rapid-acting insulin, which can be titrated in small, precise increments, Afrezza is available in unit-range cartridges that provide less granular dose adjustment. This can make matching insulin dose to carbohydrate intake more challenging in the most precise glycemic control contexts.
The study supported the conclusion that Afrezza can be safely and effectively used as a rapid-acting mealtime insulin in this population. Diabetes care is never one-size-fits-all — and that's especially true for children and adolescents.
The INHALE-1 trial's full intent-to-treat analysis for HbA1c narrowly missed the noninferiority margin, meaning Afrezza did not statistically prove it controls blood sugar as well as injected insulin in all children across the full spectrum of disease control. For children with very tightly controlled diabetes or for those at high risk for hypoglycemia, the conversation with the pediatric endocrinology team should include a careful review of the dosing data.
On pulmonary safety, two real-world evidence studies published earlier in 2026 found no statistically significant association between inhaled insulin use and long-term lung cancer risk when compared with subcutaneous insulin. Inhaled insulin has more than a decade of postmarketing history without new safety signals, though long-term independent surveillance data remain limited.
MedicalDaily Evidence Check
- Drug : Afrezza (insulin human inhalation powder; MannKind Corporation)
- FDA approval for pediatric use : May 29, 2026
- Approved age range : 6 years and older with type 1 or type 2 diabetes
- Study basis : INHALE-1 Phase 3 randomized trial; 26 weeks; pediatric patients ages 4–17
- What it found : Comparable blood sugar control (noninferiority near-missed in full ITT); less weight gain; higher treatment satisfaction
- What it did not prove: Strict HbA1c noninferiority in the full intent-to-treat population
- Key limitation : Dosing is less granular than injectable insulin; not appropriate for all children
- What readers should know : Afrezza is a new option for appropriate pediatric candidates, not a universal replacement for injected insulin — the decision requires a conversation with a pediatric endocrinologist
Who Is Most Affected?
Approximately 314,000 children and adolescents in the United States have type 1 diabetes and require mealtime insulin. Subgroups most likely to benefit from this approval include:
- Children ages 6 to 12 with documented injection anxiety causing missed doses
- Teenagers managing diabetes independently in school settings
- Children whose HbA1c indicates poorly controlled diabetes that correlates with low treatment adherence
- Families managing the psychological burden of years of daily injections on both children and parents
Afrezza is notindicated for:
- Children under age 6
- Adults or children with chronic lung disease (asthma, COPD, chronic bronchitis), for whom the inhaled route may not be safe
- People who smoke or who quit smoking in the prior 6 months
Symptoms and Warning Signs to Watch For
Parents of children starting Afrezza should monitor for:
- Hypoglycemia (low blood sugar): shakiness, sweating, rapid heartbeat, confusion, or loss of consciousness. Afrezza is ultra-rapid-acting; timing with meals is important.
- Respiratory symptoms after inhalation: cough or throat irritation is common; wheezing or shortness of breath warrants evaluation and possible discontinuation
- Signs of inadequate glycemic control : increased thirst, frequent urination, fatigue — indicating that inhaled dose titration may need adjustment
What You Can Do Now
- Talk with your child's pediatric endocrinologist about whether Afrezza is an appropriate option for their specific diabetes management needs.
- Ask specifically about pulmonary evaluation requirements — a spirometry (lung function) test is required before starting Afrezza and periodically during treatment.
- Review the dosing structure with your diabetes care team — because Afrezza comes in unit-range cartridges rather than continuous units, matching it to carbohydrate counting requires specific instruction.
- Families at school should update the 504 plan or diabetes management plan to include inhaled insulin as a permitted medication.
- Contact MannKind about savings programs: eligible people with commercial insurance may pay as little as $25 per month with the Foundayo savings card, and Afrezza pricing information is available directly from MannKind.
Cost and Access: What Patients Should Know
Afrezza for pediatric patients will be covered under most private insurance plans that include MannKind's drug in their formulary. Coverage varies; prior authorization may be required. Parents should verify coverage through their insurance's pharmacy benefits line.
For families without insurance or with limited coverage, MannKind offers patient assistance programs. Contact MannKind directly for current access pathways.
The American Diabetes Association's T1D Resource Center also maintains a listing of financial assistance programs for insulin and diabetes supplies.
What Happens Next
MannKind is conducting INHALE-1st, a Phase 2 study specifically evaluating Afrezza in youth ages 10 to 17 with newly diagnosed stage 3 type 1 diabetes — testing whether early use of inhaled insulin might preserve beta cell function at diagnosis.
Long-term post-approval safety surveillance for pulmonary function will continue as part of the label requirements. MedicalDaily will report on ISPAD conference data, long-term safety results, and insurance coverage updates as they emerge.
The Bottom Line
For the first time, children with type 1 diabetes ages 6 and older have a FDA-approved mealtime insulin that requires no injection — a milestone that directly addresses one of the most documented barriers to insulin adherence in pediatric diabetes care. Afrezza is not a replacement for all aspects of insulin therapy, and it is not appropriate for every child. But for the subset of children whose compliance and quality of life are significantly affected by needle anxiety and injection burden, this approval opens a genuinely new clinical pathway. The conversation to have next is with your child's pediatric endocrinologist.
